Both the uninterrupted and interrupted DOAC protocols revealed a low risk of symptomatic thromboembolisms and major bleeding events and similar incidence of SCILs and minor bleeding events and may be feasible for periprocedural anticoagulation in NVAF patients undergoing catheter ablation.
BACKGROUND
The selection of endoscopic treatments for superficial non-ampullary duodenal epithelial tumors (SNADETs) is controversial.
AIM
To compare the efficacy and safety of endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) for SNADETs.
METHODS
We retrospectively analyzed the data of patients with SNADETs from a database of endoscopic treatment for SNADETs, which included eight hospitals in Fukuoka, Japan, between April 2001 and October 2017. A total of 142 patients with SNADETs treated with EMR or ESD were analyzed. Propensity score matching was performed to adjust for the differences in the patient characteristics between the two groups. We analyzed the treatment outcomes, including the rates of
en bloc
/complete resection, procedure time, adverse event rate, hospital stay, and local or metastatic recurrence.
RESULTS
Twenty-eight pairs of patients were created. The characteristics of patients between the two groups were similar after matching. The EMR group had a significantly shorter procedure time and hospital stay than those of the ESD group [median procedure time (interquartile range): 6 (3-10.75) min
vs
87.5 (68.5-136.5) min,
P
< 0.001, hospital stay: 8 (6-10.75) d
vs
11 (8.25-14.75) d,
P
= 0.006]. Other outcomes were not significantly different between the two groups (
en bloc
resection rate: 82.1%
vs
92.9%,
P
= 0.42; complete resection rate: 71.4%
vs
89.3%,
P
= 0.18; and adverse event rate: 3.6%
vs
17.9%,
P
= 0.19, local recurrence rate: 3.6%
vs
0%,
P
= 1; metastatic recurrence rate: 0% in both). Only one patient in the ESD group underwent emergency surgery owing to intraoperative perforation.
CONCLUSION
EMR has significantly shorter procedure time and hospital stay than ESD, and provides acceptable curability and safety compared to ESD. Accordingly, EMR for SNADETs is associated with lower medical costs.
Objective The plasma eicosapentaenoic acid to arachidonic acid ratio (EPA/AA), which is determined only by dietary intake, has been attracting attention as a new risk marker for coronary artery disease (CAD). A Japanese inland prefecture, Tochigi, ranks higher mortality rate from CAD and lower seafood consumption, compared to other prefectures. The aim of this study was to investigate the EPA/AA ratio in residents of Tochigi prefecture. Methods We measured the EPA/AA ratio in patients undergoing diagnostic coronary angiography, because of suspicion for having CAD, all of whom were residents of Tochigi prefecture or its bordering area. Patients A total of 428 patients were enrolled in 5 centers. Results The median value of the EPA/AA ratio in the study patients was 0.37, which seems to be lower than the value of the whole Japan. The EPA/AA ratio was similar in patients with and without CAD. Female patients had lower EPA/AA ratios than male patients. When subjects were divided into 10-year age groups, 30-to 39-year-old male and female patients displayed similar EPA/AA ratios. However, the ratios of 50-to 59-year old female patients (p=0.001) and 60-to 69-year old female patients (p=0.034) were significantly lower than those of age-matched male patients. Conclusion In female residents of Tochigi prefecture, and particularly in menopausal female patients suspected of CAD, the EPA/AA ratio might be lower than male patients. EPA intake can help prevent cardiovascular events, especially in menopausal female residents of an area where the fish intake is low.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.